BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3043129)

  • 1. [Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate].
    Scheithauer W; Ludwig H; Zielinski C; Funovics J; Knoflach P; Müller C; Grabner G
    Leber Magen Darm; 1988 Jun; 18(3):149-55. PubMed ID: 3043129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastrointestinal tumors.
    Adenis A; Leriche N; Pion JM; Vanlemmens L; Bonneterre J
    Anticancer Res; 1996; 16(4A):2063-7. PubMed ID: 8712743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
    Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S
    Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
    Kaubisch A; Kaleya R; Haynes H; Rozenblit A; Wadler S
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):337-40. PubMed ID: 14704829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
    Merlini L; Secondo V; Mammoliti S; Bellotti P; Castello C; Gallo L
    Anticancer Res; 1994; 14(3B):1423-6. PubMed ID: 8067717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Karlin DA; Stroehlein JR; Bennetts RW; Jones RD; Heifetz LJ; Mahal PS
    Cancer Treat Rep; 1982 Aug; 66(8):1613-7. PubMed ID: 7105051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial.
    Takada T; Nimura Y; Katoh H; Nagakawa T; Nakayama T; Matsushiro T; Amano H; Wada K
    Hepatogastroenterology; 1998; 45(24):2020-6. PubMed ID: 9951857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
    Tsujie M; Nakamori S; Tanaka E; Nagano H; Umeshita K; Dono K; Sakon M; Inoue T; Inoue T; Monden M
    Jpn J Clin Oncol; 2006 Aug; 36(8):504-10. PubMed ID: 16855011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
    Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer.
    Ikeda M; Okada S; Ueno H; Okusaka T; Tanaka N; Kuriyama H; Yoshimori M
    Hepatogastroenterology; 2000; 47(33):862-5. PubMed ID: 10919048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
    Kouvaraki MA; Ajani JA; Hoff P; Wolff R; Evans DB; Lozano R; Yao JC
    J Clin Oncol; 2004 Dec; 22(23):4762-71. PubMed ID: 15570077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
    Lutz MP; Königer M; Muche R; Ellenrieder V; Steinkamp M; Adler G; Gress TM
    Z Gastroenterol; 1999 Oct; 37(10):993-7. PubMed ID: 10549093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
    Wagenaar HC; Colombo N; Vergote I; Hoctin-Boes G; Zanetta G; Pecorelli S; Lacave AJ; van Hoesel Q; Cervantes A; Bolis G; Namer M; Lhommé C; Guastalla JP; Nooij MA; Poveda A; Scotto di Palumbo V; Vermorken JB
    Gynecol Oncol; 2001 Jun; 81(3):348-54. PubMed ID: 11371121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM).
    Paul AR; Engstrom PF; Weiner LM; Steplewski Z; Koprowski H
    Hybridoma; 1986 Jul; 5 Suppl 1():S171-4. PubMed ID: 3527946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.